Skip to content
DataLookout
Menu

NCT05721222

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

StatusTerminated
PhasePhase 1/2
SponsorGenmab
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 17 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 19, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 43 words
    • Primary endpoints: 3 to 2
    • Secondary endpoints: 13 to 8
    • Site details revised at 1 of 17 sites
  2. Stopped Trial status: Recruiting to Terminated Sponsor's reason: Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolmentv18 Show 4 more changesShow less
    • Enrollment target: estimated 110 to confirmed 42
    • Primary completion date changed from estimate of Sep 15, 2026 to Nov 5, 2025
    • Study completion date changed from estimate of Dec 31, 2026 to Nov 5, 2025
    • Site details revised at 17 of 17 sites
  3. Minor Site details revised at 12 of 17 sitesv16
  4. Notable Lead sponsor: ProfoundBio US Co. to Genmabv14 Show 9 more changesShow less
    • Eligibility criteria expanded, about 1,037 words
    • Primary endpoints: 2 to 3
    • Enrollment target: 134 to 110
    • Primary completion date: Nov 30, 2026 to Sep 15, 2026
    • Study completion date: Mar 30, 2027 to Dec 31, 2026
    • Interventions: PRO1160 (Drug) to GEN1160 (Biological)
    • Secondary endpoints: 5 to 13
    • Study description expanded, about 23 words
    • Study title expanded, about 4 words
  5. Notable Primary completion date: Apr 30, 2024 to Nov 30, 2026
    • Study completion date: Apr 30, 2025 to Mar 30, 2027
    v13
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Study sites: 15 to 17v12
  2. Minor Study sites: 14 to 15v11
  3. Minor Study sites: 19 to 14v10
  4. Minor Site details revised at 1 of 19 sitesv9
  5. Minor Site details revised at 1 of 19 sitesv8
  6. Minor Study sites: 14 to 19v7
  7. Minor Site details revised at 1 of 14 sitesv6
  8. Minor Site details revised at 1 of 14 sitesv5
  9. Minor Site details revised at 2 of 14 sitesv4
  10. Minor Study sites: 9 to 14v3
  11. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 1 word
    • Study sites: 5 to 9
    • Start date changed from estimate of Mar 1, 2023 to Mar 15, 2023
    • Study title revised
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 2 years, 7 months
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
Timeframe: 28 days

Secondary (8)

Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants
Dose Escalation: Disease Control Rate (DCR)
Dose Escalation: Progression-free Survival (PFS)
Dose Escalation: Duration of Objective Response (DOR)
Dose Escalation: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes
Show 3 moreShow less
Dose Escalation: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes
Dose Escalation: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes
Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160

Arms and interventions

GEN1160Experimental

GEN1160 monotherapy in escalating doses in the dose escalation part and at the recommended phase 2 dose in the expansion parts.

Biologicals: GEN1160

Sites

17 sites in 2 countries

United States 14, China 3